After completing the CME activity, learners should be better able to:

• Critically evaluate clinical data regarding efficacy and safety of approved and investigational inhibitors of the hedgehog signaling pathway for advanced BCC
• Assess strategies for the integration of new treatment options into the standard of care for BCC and strategies to optimize patients’ selection, dosing, tolerability and duration of response while minimizing risks
• Identify current challenges in physician/patient communication in different practice settings
• Assess strategies to incorporate patients perspectives into the overall management of BCC

This activity is intended for medical oncologists, dermatologists and other healthcare professionals who treat patients with locally advanced or metastatic basal cell carcinoma.

There is no fee for this activity.

Please click here to register.

Accreditation Statement:

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:

Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)^TM.

Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Nursing Credit Information:

Purpose:
This program would be beneficial for nurses involved in the care of patients with locally advanced or metastatic basal cell carcinoma.

Credits:

2.0 ANCC Contact Hour(s)